Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events.

J Clin Med · 2021 · PMC8072634 · PMID 33923493

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp < 0.000001actually significant

Combining two trial populations, ASA, promptly started in the acute setting, showed a highly significant reduction in recurrent IS (1.6% vs. 2.3%; p < 0.000001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.